A 40-week trial presented at ADA's 85th Scientific Sessions showed that daily oral orforglipron significantly lowered blood sugar and body weight in adults with early type 2 diabetes.
A phase 3 randomized clinical trial found that cytisinicline, a partial agonist at α4β2 nicotinic acetylcholine receptors, improved smoking cessation rates compared with placebo, with higher abstinence rates and reduced craving over 24 weeks.
The FDA has approved Moderna’s mRESVIA vaccine for adults aged 18 to 59 who are at increased risk for RSV, expanding its indication beyond older adults.
2023 brought record-breaking heat waves in the United States, significantly impacting vulnerable groups. Analysis by the CDC revealed a substantial number of heat-related illness (HRI) emergency department visits, resulting in multiple public health alerts.
Results from a trial reveal that Eli Lilly's tirzepatide, a weight loss drug, reduces the risk of heart failure outcomes by 38% compared to a placebo for obese adults, with significant weight loss and improved symptoms. Novo Nordisk's Wegovy also shows promise in reducing heart failure symptoms.
The U.S. Senate Committee is calling the CEO of Steward Health to testify about alleged corporate greed and financial mismanagement amid the company's bankruptcy.